Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biotheus Acquires Rights to TILT Bio's Chimeric Adenovirus

publication date: Jan 27, 2020

Biotheus, a Guangdong biotech, in-licensed greater China rights to an oncolytic virus from Finland's TILT Biotherapeutics. TILT's proprietary technology codes novel oncolytic viruses for cytokines. The candidate, TILT-123, is a human 5/3 chimeric adenovirus capable of replicating only in cells defective in retinoblastoma/p16 pathway, which are found in most human tumors. Biotheus is developing a broad portfolio of me-better/novel drugs focused on immuno-oncology and metabolic diseases. The company plans to out-license late-stage clinical and commercialization activities to global partners. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital